BioNTech AG, a Mainz, Germany-based biotechnology company advancing individualized cancer immunotherapy, completed a $270m Series A round of financing.
The round was led by the Redmile Group and joined by Janus Henderson Investors, Invus, Fidelity Management & Research Company and several European family offices. The Struengmann Family Office, an existing investor in BioNTech, also participated in the capital raise.
The company will use the capital to further advance its clinical pipeline of individualized immunotherapies covering a number of new approaches including mRNA and CAR-T / T-Cell receptors for the treatment of cancer and other diseases.
Founded in 2008 by Prof. Ugur Sahin, CEO, BioNTech is a biopharmaceutical company advancing the development of individualized therapies for cancer and other diseases. Its technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech’s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health.